☆ 4.5 Review

Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis

MOLECULES AND CELLS (2021)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19

Lauren B. Rodda et al.

Summary: The study found that individuals recovered from mild COVID-19 develop sustained SARS-CoV-2-specific immunological memory for at least 3 months, including immunoglobulin antibodies, neutralizing plasma, and memory B and T cells. These memory lymphocytes exhibit potent antiviral function, aiding in immune defense.

CELL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

COVID-19-neutralizing antibodies predict disease severity and survival

Wilfredo F. Garcia-Beltran et al.

Summary: Severe cases of COVID-19 show increased inflammatory markers, lymphopenia, pro-inflammatory cytokines, and high antibody levels. High neutralization potency is a predictor of survival. Patient sera can neutralize different strains, indicating cross-protection from reinfection.

CELL (2021)

Add to Collection

Article Microbiology

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Allison J. Greaney et al.

Summary: Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are key in neutralizing antibody responses, and a deep mutational scanning method was used to assess the impact of all amino-acid mutations in the RBD on antibody binding with 10 human monoclonal antibodies. The study identified the clustered escape mutations in different surfaces of the RBD that correspond to structurally defined antibody epitopes, showing that even antibodies targeting the same surface can have distinct escape mutations.

CELL HOST & MICROBE (2021)

Add to Collection

Article Microbiology

D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization

Drew Weissman et al.

Summary: The D614G mutation in the spike protein of SARS-CoV-2 is not expected to hinder current vaccine development, as viruses with the G614 spike are more susceptible to neutralization, indicating that the mutation may not affect vaccine efficacy.

CELL HOST & MICROBE (2021)

Add to Collection

Article Immunology

Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection

Daniel Poston et al.

Summary: Although cross-reactive immune responses may affect SARS-CoV-2 susceptibility and disease outcomes, neutralizing activity against SARS-CoV-2 was not detected in prepandemic sera with prior seasonal coronavirus infection.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial

Robert L. Gottlieb et al.

Summary: The study showed that treatment with bamlanivimab and etesevimab was significantly associated with a reduction in SARS-CoV-2 viral load at day 11 in nonhospitalized patients with mild to moderate COVID-19, compared to placebo. However, bamlanivimab monotherapy did not show a significant reduction in viral load. Ongoing clinical trials will focus on assessing the clinical benefits of antispike neutralizing antibodies in COVID-19 patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Editorial Material Infectious Diseases

Persistence of IgG response to SARS-CoV-2

Els Duysburgh et al.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

Evolution of antibody immunity to SARS-CoV-2

Christian Gaebler et al.

Summary: After infection with SARS-CoV-2, antibody levels against the spike protein decrease significantly, but the number of memory B cells remain unchanged, indicating an evolving humoral response at 6.2 months after infection.

NATURE (2021)

Add to Collection

Article Medicine, General & Internal

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

J. Sadoff et al.

Summary: The study conducted a multicenter, placebo-controlled, phase 1-2a trial, with participants randomly assigned to receive the Ad26.COV2.S vaccine. The results showed that the safety and immunogenicity profiles of the vaccine support further development.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Audio Interview: Covid-19 in South Africa and a New SARS-CoV-2 Variant

Eric J. Rubin et al.

Summary: In an audio interview conducted on January 13, 2021, South African infectious disease physician Salim Abdool Karim joined the editors to discuss Covid-19 in Africa and the impact of a newly discovered SARS-CoV-2 variant.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen et al.

Summary: LY-CoV555, a neutralizing antibody, showed promising results in reducing viral load, improving symptoms, and lowering the risk of hospitalization among patients with mild or moderate Covid-19. While one of the doses appeared to accelerate the decline in viral load, others did not show significant effects by day 11.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Cell Biology

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Zijun Wang et al.

Summary: The IgA response to SARS-CoV-2 was characterized in a cohort of 149 convalescent individuals after COVID-19 diagnosis. IgA responses in plasma generally correlated with IgG responses, and B cells producing IgM, IgG, and IgA were derived from common progenitor cells. Notably, IgA dimers were found to be 15 times more potent than IgA monomers against SARS-CoV-2, suggesting their potential value for protection and vaccine efficacy.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Cell Biology

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Delphine Sterlin et al.

Summary: The study found that humoral immune responses to SARS-CoV-2 infection are dominated by IgA antibodies, with specific IgA plasmablasts rapidly expanding shortly after symptom onset and peaking in the third week of the disease. Virus-specific antibody responses include IgG, IgM, and IgA, with IgA playing a greater role in virus neutralization compared to IgG.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021

Summer E. Galloway et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Microbiology

Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals

Jian Zhang et al.

Summary: COVID-19 is caused by SARS-CoV-2, and the majority of convalescent individuals maintain neutralizing antibodies against SARS-CoV-2. Those who experienced severe COVID-19 had higher levels of neutralizing antibodies, a faster increase in lymphocyte counts, and a higher frequency of CXCR3(+) T-follicular help cells.

NATURE MICROBIOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Maturation and persistence of the anti-SARS-CoV-2 memory B cell response

Aurelien Sokal et al.

Summary: Memory B cells play a crucial role in host defense against SARS-CoV-2, with distinct B cell clone responses to the virus contributing to long-lasting immune protection. The study also highlights the significance of somatic mutations in the variable region genes of memory B cells over time, indicating continued maturation and long-term immune memory post-infection.

CELL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Wilfredo F. Garcia-Beltran et al.

Summary: New variants of SARS-CoV-2 show high resistance to vaccine neutralization, with some able to escape vaccine responses with just a few mutations, highlighting the importance of developing broadly protective measures against variants.

CELL (2021)

Add to Collection

Letter Medicine, General & Internal

Emergence of a Novel SARS-CoV-2 Variant in Southern California

Wenjuan Zhang et al.

Summary: The research focused on sequencing and phylogenetic analyses of SARS-CoV-2 isolates from symptomatic patients at Cedar-Sinai Medical Center in November-December 2020, providing insights into a surge in cases and hospitalizations during that period.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Multidisciplinary Sciences

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Dami A. Collier et al.

Summary: The B.1.1.7 variant of SARS-CoV-2 exhibited reduced neutralization by vaccines and antibodies from recovered COVID-19 patients, with a more substantial loss seen when introducing the E484K mutation. This mutation poses a threat to the efficacy of the BNT162b2 vaccine.

NATURE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Constantinos Kurt Wibmer et al.

Summary: The SARS-CoV-2 virus in the B.1.351 variant discovered in South Africa can evade neutralization by most antibodies when expressed, but does not affect binding by convalescent plasma. This suggests the potential for reinfection with antigenically distinct variants and predicts reduced efficacy of spike-based vaccines.

NATURE MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Sixteen novel lineages of SARS-CoV-2 in South Africa

Houriiyah Tegally et al.

Summary: The study identified 16 new lineages of SARS-CoV-2 in South Africa between March and August 2020, with unique mutations not found elsewhere. Three lineages (B.1.1.54, B.1.1.56, and C.1) dominated during the country's first wave, accounting for approximately 42% of all infections. The C.1 lineage, with 16 nucleotide mutations including the D614G spike protein change, became the most geographically widespread by August 2020. Genomic surveillance played a crucial role in identifying the 501Y.V2 variant in South Africa in December 2020.

NATURE MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Xuping Xie et al.

Summary: The study found that human sera from recipients of the BNT162b2 vaccine can neutralize SARS-CoV-2 viruses containing key spike mutations from the newly emerged UK and SA variants.

NATURE MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Alexander Muik et al.

Summary: A new SARS-CoV-2 lineage B.1.1.7 has emerged in the UK, which is more transmissible and faster spreading than other strains. However, a study found that the BNT162b2 vaccine offers largely preserved protection against the B.1.1.7 lineage, despite some reduced neutralizing titers.

SCIENCE (2021)

Add to Collection

Letter Public, Environmental & Occupational Health

Imported SARS-CoV-2 V501Y.V2 variant (B.1.351) detected in travelers from South Africa and Tanzania to India

Pragya D. Yadav et al.

TRAVEL MEDICINE AND INFECTIOUS DISEASE (2021)

Add to Collection

News Item Medicine, General & Internal

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Markus Hoffmann et al.

Summary: The emerging SARS-CoV-2 variants may exhibit resistance to existing neutralizing antibodies and treatments, which could have significant implications for pandemic containment efforts.

CELL (2021)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

Tracking the emergence of new SARS-CoV-2 variants in South Africa

Anise N. Happi et al.

Summary: A large genomic surveillance effort in South Africa identified 16 new lineages of SARS-CoV-2 through the analysis of 1,365 high-quality whole genomes, which had not been previously identified in other countries.

NATURE MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection

Ge Song et al.

Summary: This study examines the impact of pre-existing immunity to seasonal endemic coronaviruses on antibody responses to SARS-CoV-2, finding weak evidence of pre-existing cross-reactive serum antibodies in pre-pandemic donors, but evidence of pre-existing cross-reactive memory B cells activated during SARS-CoV-2 infection. Monoclonal antibodies show varying degrees of cross-reactivity with betacoronaviruses, and one neutralizing antibody specific to the S2 subunit of the S protein is identified, suggesting that pre-existing immunity to endemic coronaviruses should be considered in evaluating antibody responses to SARS-CoV-2.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Immunology

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization

Jing Zou et al.

Summary: The D614G mutation modestly reduced SARS-CoV-2 neutralization by sera elicited from BNT162b2 vaccine in mice, rhesus monkeys, and humans, but the vaccine efficacy was consistent with the 95% observed in clinical trials.

NPJ VACCINES (2021)

Add to Collection

Letter Infectious Diseases

Discovery of a SARS-CoV-2 variant from the P.1 lineage harboring K417T/E484K/N501Y mutations in Kofu, Japan

Yosuke Hirotsu et al.

JOURNAL OF INFECTION (2021)

Add to Collection

Letter Immunology

Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil

Carolina Kymie Vasques Nonaka et al.

Summary: The case of reinfection from distinct virus lineages in Brazil with the E484K mutation raises concerns about the duration of protective immune responses against SARS-CoV-2, especially with the variant associated with escape from neutralizing antibodies. This highlights potential challenges for virus control measures.

EMERGING INFECTIOUS DISEASES (2021)

Add to Collection

Letter Immunology

Novel SARS-CoV-2 Variant in Travelers from Brazil to Japan

Takahisa Fujino et al.

Summary: Different variants of SARS-CoV-2 with higher transmission potential have been emerging globally, including one found in travelers from Brazil to Japan in January 2021, which carries an additional set of mutations.

EMERGING INFECTIOUS DISEASES (2021)

Add to Collection

Letter Immunology

Local Transmission of SARS-CoV-2 Lineage B.1.1.7, Brazil, December 2020

Ingra Morales Claro et al.

Summary: In December 2020, the B.1.1.7 lineage of SARS-CoV-2 was detected in Sao Paulo, Brazil, with two distinct introductions identified through rapid genomic sequencing. There may be more infections with this lineage in Brazil than officially reported.

EMERGING INFECTIOUS DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans

Bas B. Oude Munnink et al.

Summary: Animal experiments have shown that various animals can be infected by SARS-CoV-2, with evidence of animal-to-human transmission within mink farms. Investigation into mink farm outbreaks revealed that the virus was initially introduced by humans and has since evolved, causing transmission between mink farms. Despite enhanced biosecurity measures and culling, transmission occurred between farms in three large clusters with unknown modes of transmission, resulting in a high percentage of infections among mink farm residents and employees.

SCIENCE (2021)

Add to Collection

Article Immunology

Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019

Juanjuan Zhao et al.

CLINICAL INFECTIOUS DISEASES (2020)

Add to Collection

Article Immunology

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

Xiaolong Tian et al.

EMERGING MICROBES & INFECTIONS (2020)

Add to Collection

Review Pediatrics

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents A Systematic Review

Riccardo Castagnoli et al.

JAMA PEDIATRICS (2020)

Add to Collection

Article Multidisciplinary Sciences

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Rui Shi et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Bin Ju et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Cross-neutralization ofSARS-CoV-2 by a human monoclonal SARS-CoV antibody

Dora Pinto et al.

NATURE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Qianqian Li et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Yunlong Cao et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Bette Korber et al.

CELL (2020)

Add to Collection

Article Immunology

Distinct Early Serological Signatures Track with SARS-CoV-2 Survival

Caroline Atyeo et al.

IMMUNITY (2020)

Add to Collection

Article Multidisciplinary Sciences

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Lihong Liu et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Potently neutralizing and protective human antibodies against SARS-CoV-2

Seth J. Zost et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

A perspective on potential antibody-dependent enhancement of SARS-CoV-2

Ann M. Arvin et al.

NATURE (2020)

Add to Collection

Letter Medicine, General & Internal

Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19

F. Javier Ibarrondo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Alina Baum et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Philip J. M. Brouwer et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Christopher O. Barnes et al.

NATURE (2020)

Add to Collection

Article Immunology

Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19

Matthew C. Woodruff et al.

NATURE IMMUNOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Humoral Immune Response to SARS-CoV-2 in Iceland

Daniel F. Gudbjartsson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Alina Baum et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Paul Bastard et al.

SCIENCE (2020)

Add to Collection

Article Microbiology

S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit

Phuong Nguyen-Contant et al.

MBIO (2020)

Add to Collection

Article Microbiology

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Jeffrey Seow et al.

NATURE MICROBIOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals

Yuanmei Zhu et al.

SCIENCE ADVANCES (2020)

Add to Collection

Article Medicine, General & Internal

Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study

Mar Masia et al.

EBIOMEDICINE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality

Tomer Zohar et al.

CELL (2020)

Add to Collection

Article Virology

Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients

Anwar M. Hashem et al.

VIRUSES-BASEL (2020)

Add to Collection

Article Virology

Multiple Introductions Followed by Ongoing Community Spread of SARS-CoV-2 at One of the Largest Metropolitan Areas of Northeast Brazil

Marcelo Henrique Santos Paiva et al.

VIRUSES-BASEL (2020)

Add to Collection

Article Immunology

Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome

Katharina Roltgen et al.

SCIENCE IMMUNOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Kevin W. Ng et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Ania Wajnberg et al.

SCIENCE (2020)

Add to Collection

Article Immunology

Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence

Gemma E. Hartley et al.

SCIENCE IMMUNOLOGY (2020)

Add to Collection

Article Medicine, Research & Experimental

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

Li Liu et al.

JCI INSIGHT (2019)

Add to Collection

© Peeref 2019-2024. All rights reserved.